A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)

NCT02373202 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

91

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Sarilumab
DRUG: Sulfasalazine
DRUG: Leflunomide
DRUG: Bucillamine
DRUG: Tacrolimus
DRUG: Mizoribine

Sponsor

Sanofi

Collaborators

[object Object]